DUALITYBIO-B(09606): The Shanghai Stock Exchange has accepted the application materials for the issuance of RMB shares.
Ying En Biology-B (09606) announced that the company has submitted application materials related to the issuance of RMB shares to the Shanghai Stock Exchange, including the prospectus for the initial public offering of RMB ordinary shares (A shares) and listing on the science and technology innovation board, and has recently received a receipt of acceptance from the Shanghai Stock Exchange for the company's application for the issuance of RMB shares. The prospectus for A shares will be published on the Shanghai Stock Exchange website (http://www.sse.com.cn).
DUALITYBIO-B (09606) Announces that the company has submitted the application materials for the issuance of Renminbi shares to the Shanghai Stock Exchange, including the prospectus for the initial public offering of Renminbi ordinary shares (A shares) and listing on the Sci-Tech Innovation Board, and has recently received the acknowledgement from the Shanghai Stock Exchange regarding the company's application for the issuance of Renminbi shares. The A share prospectus will be published on the Shanghai Stock Exchange website (http://www.sse.com.cn).
Related Articles

Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?

New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.

How strong is the demand for SpaceX (SPCX.US) IPO? Oversubscribed subscriptions, "greenshoe" exemption from commission, and options expected to open next week!
Buying low on Shenzhen Hepalink Pharmaceutical Group (09989) for two consecutive months, will the Hong Kong Stock Connect funds soon witness the reversal of the heparin cycle?

New Stock News | Leading supply chain company Andes Zhilian's Hong Kong IPO prospectus updated, achieving double high increase in revenue and net profit.

How strong is the demand for SpaceX (SPCX.US) IPO? Oversubscribed subscriptions, "greenshoe" exemption from commission, and options expected to open next week!

RECOMMEND





